# Novel Kidney Injury Tools in Deceased Organ Donation to Predict Graft Outcomes

> **NIH NIH R01** · JOHNS HOPKINS UNIVERSITY · 2020 · $718,018

## Abstract

Abstract
The incidence of AKI is 20-30% in patients hospitalized with COVID-19 in the United States, and
is over 40% in patients admitted to the ICU. Moreover, the mortality rate in patients that
experience AKI in the setting of COVID-19 is approximately 2- to 10-fold higher than patients
without AKI. The pathogenesis of AKI in COVID-19 infection remains unclear and it is not known
if the injury to the tubule is direct result of the virus infection or if it is secondary to other organ
complications. Availability of urine, blood and tissue samples early in the course of infection will
provide important pathogenic insights for therapeutic and clinical management.
The Translational Research investigating Biomarker Endpoints (TRIBE)-AKI consortium has a
long-standing history of conducting multidisciplinary epidemiologic and translational research
studies in the setting of AKI. They have experience with long term follow-up of hospitalized
patients, tissue and sample handling as well as analytic considerations. We propose a
prospective observational study of the clinical and biologic predictors of major adverse kidney
events and death (MAKE-D) in COVID-19, including the following: severity of AKI (stages 1, 2,
3 and requiring dialysis), mortality, and non-recovery of AKI and transition to chronic kidney
disease.
We will examine consecutive patients hospitalized with COVID-19 at three premier academic
hospitals participating in the TRIBE consortium: Johns Hopkins Medicine, Mount Sinai Hospital
and Yale-New Haven Hospital. We assess the incidence, severity, and clinical predictors of
MAKE-D during hospitalization and at 90 days following discharge. We will investigate the
possible role of injury, inflammation and repair mechanisms through biomarkers in the blood
and urine in serial samples collected from patients during hospitalization. We will also perform
advanced evaluation of kidney biopsies using single cell RNA sequencing to identify possible
mechanistic disease pathways, which may lead to novel therapeutic targets.
Combating this pandemic will require a multidisciplinary approach from the medical research
community, including rigorously conducted epidemiologic studies that include granular patient-
level data and translational research studies to understand the pathogenesis of COVID-
associated kidney disease.

## Key facts

- **NIH application ID:** 10177020
- **Project number:** 3R01DK093770-09S1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Chirag R Parikh
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $718,018
- **Award type:** 3
- **Project period:** 2012-08-15 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10177020

## Citation

> US National Institutes of Health, RePORTER application 10177020, Novel Kidney Injury Tools in Deceased Organ Donation to Predict Graft Outcomes (3R01DK093770-09S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10177020. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*